GlassScriptPhysician profile
Martin L Gnoni
NPI 1184983306
$193,933.92
in general payments reported to CMS, 2019-2025
27 companies · $57K in 2025
The $57K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $821 · 2021: $9,753 · 2022: $41K · 2023: $38K · 2024: $47K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Travel and Lodging: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Food and Beverage: $10K · Honoraria: $8,670 · Consulting Fee: $4,740 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,317.50 |
| Travel and Lodging | $18,259.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $16,435.00 |
| Food and Beverage | $10,345.71 |
| Honoraria | $8,670.00 |
| Consulting Fee | $4,740.00 |
| Education | $307.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,320.57 | 2019-2025 | |
| Shionogi INC | $47,260.99 | 2020-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $27,282.45 | 2019-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $16,884.13 | 2021-2025 | Xerava, Zevtera, Xacduro |
| Insmed, INC. | $9,170.22 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $6,117.82 | 2019-2024 | Cresemba |
| Gilead Sciences, INC. | $1,888.89 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,621.44 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $1,100.22 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Melinta Therapeutics, LLC | $369.06 | 2019-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Kerecis Limited | $143.39 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $114.87 | 2023 | Oasis, Grafix Pl, Stravix |
| Aimmune Therapeutics, INC. | $102.32 | 2024-2025 | Vowst |
| Allergan, INC. | $81.61 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $80.48 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $66.18 | 2020-2023 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $53.96 | 2023 | Arexvy, Shingrix |
| Mayne Pharma Commercial LLC | $45.66 | 2022 | |
| Vyera Pharmaceuticals, LLC | $41.27 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $36.28 | 2022-2023 | Prehevbrio |
| Dynavax Technologies Corporation | $26.72 | 2025 | Heplisav-B |
| Sanofi Pasteur INC. | $25.07 | 2023 | |
| Emd Serono, INC. | $24.81 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.39 | 2025 | Rebyota |
| Sunovion Pharmaceuticals INC. | $20.91 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.21 | 2025 | Vibativ |
| Pfizer INC. | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Gnoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.